Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles.

Tehraninejad ESh, Nekoo EA, Ezabadi Z, Rashidi BH, Amirchaghmaghi E, Matroud EP

Archives of medical science : AMS29 Dec 2010Cited by 8 (Europe PMC)

PMID22427771PMCIDPMC3302709DOI10.5114/aoms.2010.19306PepBankPUB-22427771

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In infertile women undergoing IVF/ICSI, mean gonadotropin use was 25.6 ampoules with Diphereline versus 25.9 with Suprefact.
In plain wordsIn women undergoing IVF/ICSI, mean gonadotropin use was 25.6 ampoules with Diphereline versus 25.9 with Suprefact.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedGonadotropin ampoules used
Study
n = 126
Comparator
Buserelin (Suprefact)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg · Single doseAs given in this study (human).
Measurements
Gonadotropin use
25.6 ampoules
Diphereline
Gonadotropin use
25.9 ampoules
Suprefact
Source sentences
Summary
In the Diphereline group, the mean number of used gonadotropins was 25.6 ±12.1 ampoules, while in the second group it was 25.9 ±8.5 ampoules.
3 context sentences(design, population, supporting numbers)
Summary · context
In this randomized clinical trial performed in Royan Institute, 126 infertile women who were first time candidates for IVF/ICSI were enrolled.
Summary · context
In one group, 62 patients received a single half dose, 1.87 mg Diphereline, in mid-luteal phase.
Summary · context
In the other group, 64 cases were treated with buserelin from the previous mid-luteal phase.
Report a problemFND-2242777101
02HumanRandomized controlled trialEfficacy outcome
In infertile women undergoing IVF/ICSI, Diphereline produced significantly more retrieved oocytes than Suprefact.
In plain wordsIn women undergoing IVF/ICSI, Diphereline produced significantly more retrieved eggs than Suprefact.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseRetrieved oocytes
Study
n = 126
Comparator
Buserelin (Suprefact)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg · Single doseAs given in this study (human).
Measurements
Retrieved oocytes
12.1
Diphereline
Retrieved oocytes
9.4
Suprefact
Source sentences
Summary
Numbers of retrieved and MII oocytes were significantly higher in the Diphereline group (12.1 ±6.3 and 9.6 ±5.5) in comparison to the Suprefact group (9.4 ±6.4 and 7.2 ±5.1).
3 context sentences(design, population, supporting numbers)
Summary · context
In this randomized clinical trial performed in Royan Institute, 126 infertile women who were first time candidates for IVF/ICSI were enrolled.
Summary · context
In one group, 62 patients received a single half dose, 1.87 mg Diphereline, in mid-luteal phase.
Summary · context
In the other group, 64 cases were treated with buserelin from the previous mid-luteal phase.
Report a problemFND-2242777102
03HumanRandomized controlled trialEfficacy outcome
In infertile women undergoing IVF/ICSI, Diphereline produced significantly more MII oocytes than Suprefact.
In plain wordsIn women undergoing IVF/ICSI, Diphereline produced significantly more mature eggs than Suprefact.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseMII oocytes
Study
n = 126
Comparator
Buserelin (Suprefact)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg · Single doseAs given in this study (human).
Measurements
MII oocytes
9.6
Diphereline
MII oocytes
7.2
Suprefact
Source sentences
Summary
Numbers of retrieved and MII oocytes were significantly higher in the Diphereline group (12.1 ±6.3 and 9.6 ±5.5) in comparison to the Suprefact group (9.4 ±6.4 and 7.2 ±5.1).
3 context sentences(design, population, supporting numbers)
Summary · context
In this randomized clinical trial performed in Royan Institute, 126 infertile women who were first time candidates for IVF/ICSI were enrolled.
Summary · context
In one group, 62 patients received a single half dose, 1.87 mg Diphereline, in mid-luteal phase.
Summary · context
In the other group, 64 cases were treated with buserelin from the previous mid-luteal phase.
Report a problemFND-2242777103
04HumanRandomized controlled trialEfficacy outcome
In infertile women undergoing IVF/ICSI, Diphereline produced significantly more developed embryos than Suprefact.
In plain wordsIn women undergoing IVF/ICSI, Diphereline produced significantly more developed embryos than Suprefact.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseDeveloped embryos
Study
n = 126
Comparator
Buserelin (Suprefact)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg · Single doseAs given in this study (human).
Measurements
Developed embryos
6.1
Diphereline
Developed embryos
4.7
Suprefact
Source sentences
Summary
Although the number of developed embryos in the Diphereline group was statistically higher than in the Suprefact group (6.1 ±3.9 vs. 4.7 ±3.4, p = 0.04) there was no significant difference in pregnancy rate (37.1%, 95% CI [26.16-49.54] vs. 37.5%, 95% CI [26.67-49.75]).
3 context sentences(design, population, supporting numbers)
Summary · context
In this randomized clinical trial performed in Royan Institute, 126 infertile women who were first time candidates for IVF/ICSI were enrolled.
Summary · context
In one group, 62 patients received a single half dose, 1.87 mg Diphereline, in mid-luteal phase.
Summary · context
In the other group, 64 cases were treated with buserelin from the previous mid-luteal phase.
Report a problemFND-2242777104
05HumanRandomized controlled trialEfficacy outcome
In infertile women undergoing IVF/ICSI, pregnancy rates did not differ significantly between Diphereline and Suprefact.
In plain wordsIn women undergoing IVF/ICSI, pregnancy rates did not differ significantly between Diphereline and Suprefact.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePregnancy rate
Study
n = 126
Comparator
Buserelin (Suprefact)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg · Single doseAs given in this study (human).
Measurements
Pregnancy rate
37.1%
Diphereline
Pregnancy rate
37.5%
Suprefact
Source sentences
Summary
Although the number of developed embryos in the Diphereline group was statistically higher than in the Suprefact group (6.1 ±3.9 vs. 4.7 ±3.4, p = 0.04) there was no significant difference in pregnancy rate (37.1%, 95% CI [26.16-49.54] vs. 37.5%, 95% CI [26.67-49.75]).
3 context sentences(design, population, supporting numbers)
Summary · context
In this randomized clinical trial performed in Royan Institute, 126 infertile women who were first time candidates for IVF/ICSI were enrolled.
Summary · context
In one group, 62 patients received a single half dose, 1.87 mg Diphereline, in mid-luteal phase.
Summary · context
In the other group, 64 cases were treated with buserelin from the previous mid-luteal phase.
Report a problemFND-2242777105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.